Levodopa/carbidopa/entacapone + Levodopa/carbidopa

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Oct 1, 2006 → Jun 1, 2008

About Levodopa/carbidopa/entacapone + Levodopa/carbidopa

Levodopa/carbidopa/entacapone + Levodopa/carbidopa is a approved stage product being developed by Novartis for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00391898. Target conditions include Parkinson's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease were approved

Approved (20) Terminated (4) Active (0)

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00391898ApprovedCompleted

Competing Products

20 competing products in Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
19
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
35
E2007EisaiPhase 3
32
ARICEPTEisaiPhase 3
40
PerampanelEisaiPhase 3
32
GPI 1485EisaiPhase 2
35
E2007EisaiPhase 3
40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
40
perampanel + placeboEisaiPhase 2
27
Lemborexant + placeboEisaiApproved
50
Placebo + E2007 + E2007EisaiPhase 3
32
E2007 + E2007 + E2007EisaiPhase 2
35
E2007EisaiPhase 2
35
E2007EisaiPhase 2
27
E2007EisaiPhase 2
27
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
40
Istradefylline (KW-6002)Kyowa KirinPhase 2
35
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
40
Istradefylline (KW-6002)Kyowa KirinPhase 3
40